Results 261 to 270 of about 142,523 (351)

Emerging role of G protein‐coupled receptor class C group 5 member D‐directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies

open access: yesBritish Journal of Haematology, EarlyView.
Summary Multiple myeloma (MM) is a clonal malignancy of plasma cells characterized by frequent relapse and therapeutic resistance. G protein‐coupled receptor class C group 5 member D (GPRC5D) has emerged as a promising immunotherapeutic target due to its high and selective expression in MM cells and minimal presence in normal tissues.
Xueting Wang   +3 more
wiley   +1 more source

Glucose sensing and homeostasis by adipocyte GPCR. [PDF]

open access: yesFront Endocrinol (Lausanne)
Hasan N, Chhabra KH.
europepmc   +1 more source

Artificial intelligence streamlines scientific discovery of drug–target interactions

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Drug discovery is a complicated process through which new therapeutics are identified to prevent and treat specific diseases. Identification of drug–target interactions (DTIs) stands as a pivotal aspect within the realm of drug discovery and development. The traditional process of drug discovery, especially identification of DTIs, is marked by
Yuxin Yang, Feixiong Cheng
wiley   +1 more source

Arrestins as Possible Drug Targets. [PDF]

open access: yesBiomol Ther (Seoul)
Cinviz ZN   +4 more
europepmc   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Is helix VIII of G protein‐coupled receptors (GPCRs) a lipid‐activated signalling sensor?

open access: hybrid, 2007
John Huynh   +3 more
openalex   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy